Hartej Gill

Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Hartej Gill appears in 8 tracked papers (2020–2023), most studied alongside Ketamine, Psilocybin and MDMA, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).

Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).

Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Maria Rodrigues.

Background & Research

Hartej Gill is a researcher associated with the Mood Disorders Psychopharmacology Unit at the University Health Network and the University of Toronto in Toronto, Canada. Their publications include systematic reviews and meta-analyses on ketamine’s antidepressant, antisuicidal, and cognitive effects, as well as work on registered clinical studies of psychedelic drugs for psychiatric disorders. Recent article listings identify Gill as a corresponding author on this research program.

Key Impact

Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

18 collaborators· click a node to visit their profile

Full network →

Compounds

KetaminePsilocybinMDMAEsketamine

Topics

Depressive DisordersAnxiety DisordersMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)SuicidalityBipolar DisorderSafety & Risk ManagementPTSDEquity and EthicsAdolescentsNeurocognitive DisordersSchizophreniaBorderline Personality Disorder (BPD)Personality DisordersAlcohol Use Disorder (AUD)Substance Use Disorders (SUD)Neuroimaging & Brain MeasuresHealthy VolunteersMedicinal Chemistry & Drug DevelopmentObsessive-Compulsive Disorder (OCD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Hartej Gill is associated with.

University of Toronto

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.

View stakeholder →

Brain and Cognition Discovery Foundation

Non-Profit

Canada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.

View stakeholder →